- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00214903
European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT)
European Active Surveillance Study of Women Taking HRT
Study Overview
Status
Conditions
Detailed Description
The safety of a novel drug product containing a new chemical entity should be assessed in an extensive post marketing safety surveillance program. It is also prudent to assess both, the safety outcomes that relate specifically to the targeted population, as well as those that could potentially be related to the special pharmacological characteristics of the novel drug product. Differentiating between the inherent background population risk and a potential incremental risk due to treatment is often challenging. Active safety surveillance using valid epidemiological study designs has been proven to be a pertinent and reliable method to approach this endeavour.
The primary objective of the study, the European Active Surveillance Study of Women taking HRT (EURAS-HRT), is to compare incidence rates of serious adverse events in users of all types of newly prescribed oral continuous combined HRT products. This active surveillance study will assess pertinent cardiovascular outcomes in new HRT users over a study period of up to 8.5 years. Also, all other serious adverse events will be reported.
The new drug product under surveillance in the EURAS - HRT study contains the novel synthetic progestagen drospirenone (DRSP) combined with estradiol.
As estrogen/progestagen combinations increase the risk for thromboembolism, all new drug products that contain a novel estrogen or progestagen should be investigated for their influence on venous and arterial thromboembolic events rates. A large, prospective, controlled cohort study of OC users (EURAS OC study), which compared DRSP-containing OC users with other OC users, demonstrated that DRSP is not associated with an increased incidence for any of the above-mentioned adverse events in OC users. However, because OC users are two to three decades younger than the typical HRT user the results of the OC study can only partially be extrapolated to older age groups.
The participating women will complete a baseline survey using a self-administered questionnaire to describe the baseline risk. After 6 months, 12 months, and then on an annual basis, they will fill out a questionnaire in which they record complaints and events during the use of the prescribed HRTs. All adverse outcomes (including cancer) occurring during the observational period will be evaluated additionally. Reported serious adverse events will be validated and analyzed. As study participants may switch from oral continuous combined products to other oral or non-oral HRT products the outcomes for these preparation are recorded too. However, these results represent not the scientific focus of the study.
Based on experience obtained in previous HRT studies, complex sources of bias and confounding are expected. Multivariate methods will therefore be used to adjust for confounding.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10115
- Center for Epidemiology and Health Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All women aged 40 or more years who started use of a new oral HRT at the time of inclusion in the study
Exclusion Criteria:
- Women who do not consent to participate in the study
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
1
New users of oral continuous combined HRT containing drospirenone
|
2
New users of oral continuous combined HRT containing other progestagens
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Venous Thromboembolism (e.g., Deep Venous Thrombosis and Pulmonary Embolism)
Time Frame: within 8.5 years
|
Venous thromboembolism (VTE) linked to the use of continuous combined HRT containing both drospirenone (DRSP) and estradiol (E2) or to other oral continuous combined HRT preparations.
|
within 8.5 years
|
Arterial Thromboembolism (e.g., Acute Myocardial Infarction and Stroke)
Time Frame: within 8.5 years
|
Arterial thromboembolism (ATE) linked to the use of continuous combined HRT containing both drospirenone (DRSP) and estradiol (E2) or to other oral continuous combined HRT preparations.
|
within 8.5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Juergen Dinger, MD, PhD, ZEG, Invalidenstrasse 115, 10115 Berlin, Germany
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ZEG 2000_3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menopausal Symptoms
-
Angelica Lindén HirschbergRecruiting
-
Northumbria UniversityDoctor SeaweedCompletedMenopausal Syndrome | Menopausal DepressionUnited Kingdom
-
Beth Israel Deaconess Medical CenterNichimo - Tokyo, JapanCompleted
-
Adiyaman University Research HospitalCompleted
-
Guang'anmen Hospital of China Academy of Chinese...Ministry of Science and Technology of the People´s Republic of ChinaCompletedMenopausal SyndromeChina
-
University PotiguarFederal University of São Paulo; InBios International, Inc.Completed
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
BayerNerre Therapeutics Ltd.CompletedPost-menopausal Vasomotor SymptomsUnited States
-
Novo Nordisk A/SCompletedMenopause | Menopausal Vasomotor SymptomsDenmark, United Kingdom, Sweden, Belgium, Switzerland, Germany, France, Finland, Austria, Norway